Manufacturing process platforms in the biopharmaceutical industry are evolving from low biomass, large volume fed-batch processes to include continuous, sustained high biomass, small volume processes. This transition provides the opportunity for advancing innovative solutions to new process development challenges. During the development of one such intensified process, several different cell culture process modes were evaluated: steady state perfusion, non-steady state intensified batch and fed-batch. Productivity remained constant through the duration of the culture for the non-steady state intensified batch and fed-batch process modes but decreased in the steady state perfusion mode. Interestingly, the overall productivity was found to correlate negatively with culture viabilities. Investigation of this decrease in productivity revealed a correlation to cell age and subsequently to a decline in copy number. Implementation of selective medium for perfusion effectively reversed the decline in productivity, maintaining it without impact to product quality. As platforms in the biopharmaceutical industry continue to evolve, these solutions can be leveraged in the development of a robust perfusion process.

Maintaining productivity over extended durations for perfusion processes

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.